ENHERTU® Recommended for Approval in the EU by CHMP for Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer Following at Least One Endocrine TherapyContributed by: Business WireLogoTagsBiotechnologyHealthPharmaceuticalClinical TrialsOncologyDaiichi Sankyo